ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

No reading has been made of this study yet; what is shown is how our rules link it today.

2 links0 made here, not in the record3 judgments1 judge (our rules as one)0 record changes seen
Our rules
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT02202746A Study to Assess theSafety and Efficacy of theVEGFR-FGFR-PDGFR Inhibitor,Lucitanib, Given toPatients With MetastaticBreast CancerClovis Oncology, Inc.Phase 2 · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBreast NeoplasmsThe registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termAs of now · Our main-condition rule (R9) · Main conditionMain conditionDRUGSE-3810Entry “Lucitanib”, read by our name r…›As of now · Our role rule · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Breast Neoplasms

From the registry record2 judgments on this link
Kind of condition link, from the registry to what was judged
RegistryBreast Neoplasms, as filedthe registry files the study under it
→judged
Main condition (R9)

All judgments on this study

WhenLinkJudgeDecisionState
Nov 14Breast NeoplasmsOur condition-kind ruleFinest filed termCurrent
As of nowBreast NeoplasmsOur main-condition rule (R9)Main conditionCurrent
As of nowE-3810Our role ruleTestedCurrent